OTCMKTS:CPHRF Cipher Pharmaceuticals (CPHRF) Stock Forecast, Price & News $3.18 -0.05 (-1.55%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$2.50▼$3.1950-Day Range$2.56▼$3.3452-Week Range$1.31▼$5.38Volume9,000 shsAverage Volume6,536 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsHeadlinesShort InterestProfileAnalyst RatingsChartCompetitorsHeadlinesShort Interest About Cipher Pharmaceuticals (OTCMKTS:CPHRF) StockCipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne; Lipofe indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.Read More CPHRF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPHRF Stock News HeadlinesSeptember 22, 2023 | americanbankingnews.comCipher Pharmaceuticals (OTCMKTS:CPHRF) Stock Price Crosses Above 50-Day Moving Average of $2.88June 1, 2023 | markets.businessinsider.comCipher Pharmaceuticals (CPHRF) Receives a Buy from Stifel NicolausSeptember 29, 2023 | Tradewins (Ad)Successful Options Trading Begins With…Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month! May 17, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc up on Wednesday (CPH)May 11, 2023 | seekingalpha.comCipher Pharmaceuticals GAAP EPS of $0.10 beats by $0.02, revenue of $4.9M misses by $0.64MMay 11, 2023 | finance.yahoo.comCipher Pharmaceuticals Reports First Quarter Results, Highlighted by Record Cash Per Share and Strong Financial FlexibilityMay 2, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc down on Tuesday (CPH)May 2, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc up on Monday (CPH)September 29, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.April 27, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc down on Thursday (CPH)April 21, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc down on Friday (CPH)April 7, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc up on Thursday (CPH)March 20, 2023 | seekingalpha.comCipher Pharmaceuticals Inc. (CPHRF) Q4 2022 Earnings Call TranscriptMarch 17, 2023 | markets.businessinsider.comCipher Pharmaceuticals earnings: here's what Wall Street expectsMarch 10, 2023 | finance.yahoo.comCipher Pharmaceuticals Schedules Q4 2022 Earnings Release and Conference CallJanuary 31, 2023 | finance.yahoo.comCipher Pharmaceuticals (TSE:CPH) shareholders have earned a 51% CAGR over the last three yearsJanuary 13, 2023 | finanznachrichten.deCypher Core, Inc: CIPHER-CORE, Inc. President Addresses Company's Business DirectionNovember 11, 2022 | ca.finance.yahoo.comCipher Pharmaceuticals Inc. (CPHRF)November 10, 2022 | finance.yahoo.comCipher Pharmaceuticals Reports Strong Third Quarter Results, Highlighted by USD$1.09 in Cash Per ShareAugust 24, 2022 | finance.yahoo.comInvesting in Cipher Pharmaceuticals (TSE:CPH) three years ago would have delivered you a 107% gainAugust 12, 2022 | seekingalpha.comCipher Pharmaceuticals Inc. (CPHRF) CEO Craig Mull on Q2 2022 Results - Earnings Call TranscriptAugust 11, 2022 | finance.yahoo.comCipher Pharmaceuticals Strengthens Leadership Team with Appointment of New CFOJuly 9, 2022 | theglobeandmail.comCipher Pharmaceuticals Inc stock boosted on Friday.May 14, 2022 | seekingalpha.comCipher Pharmaceuticals GAAP EPS of C$0.08, revenue of C$5.4MMarch 24, 2022 | finance.yahoo.comIs Now The Time To Put Cipher Pharmaceuticals (TSE:CPH) On Your Watchlist?March 22, 2022 | finance.yahoo.comCipher Pharmaceuticals Announces Partner, Moberg Pharma's Regulatory Submission to FDA for North American Phase 3 StudyMarch 18, 2022 | benzinga.comMariMed Doubles Full Year Revenue And Adjusted EBITDA, Reports Q4 & Full Year EarningsSee More Headlines Receive CPHRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPHRF Company Calendar Last Earnings5/05/2016Today9/29/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Drug Manufacturers—Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CPHRF Previous SymbolNASDAQ:CPHR CUSIPN/A CIKN/A Webwww.cipherpharma.com Phone(905) 602-5840FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Craig J. MullInterim CEO & ChairmanMr. Bryan JacobsChief Financial OfficerDr. Diane GajewczykVP of Scientific & Medical AffairsMr. Emilio PrestiDirector of Sales & MarketingKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbattis BioceuticalsOTCMKTS:ATTBFView All Competitors CPHRF Stock - Frequently Asked Questions Should I buy or sell Cipher Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPHRF shares. View CPHRF analyst ratings or view top-rated stocks. How have CPHRF shares performed in 2023? Cipher Pharmaceuticals' stock was trading at $2.7949 at the beginning of 2023. Since then, CPHRF shares have increased by 13.9% and is now trading at $3.1847. View the best growth stocks for 2023 here. Are investors shorting Cipher Pharmaceuticals? Cipher Pharmaceuticals saw a drop in short interest during the month of September. As of September 15th, there was short interest totaling 1,100 shares, a drop of 15.4% from the August 31st total of 1,300 shares. Based on an average trading volume of 16,300 shares, the short-interest ratio is currently 0.1 days. View Cipher Pharmaceuticals' Short Interest. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) released its earnings results on Thursday, May, 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.06. The company earned $9.10 million during the quarter, compared to analysts' expectations of $10.87 million. What is Cipher Pharmaceuticals' stock symbol? Cipher Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CPHRF." How do I buy shares of Cipher Pharmaceuticals? Shares of CPHRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cipher Pharmaceuticals' stock price today? One share of CPHRF stock can currently be purchased for approximately $3.18. How can I contact Cipher Pharmaceuticals? Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The official website for the company is www.cipherpharma.com. The company can be reached via phone at (905) 602-5840. This page (OTCMKTS:CPHRF) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.